AbbVie lowers profit forecast by $2.7 billion due to IPR&D expenses in Q3, now expecting adjusted EPS between $10.38 and $10.58 for the year. Analysts anticipated $12.02. New $195 million plant in North Chicago to produce medicines by 2027. Company relies on new drugs to counter Humira sales decline.

Read more at Yahoo Finance: AbbVie trims annual profit forecast after expected $2.7 billion R&D hit